All Substitutes
Loading...
Disclaimer
Did you find this information helpful?
Kadcyla 160mg Injection
Prescription Required
Salt Composition : Ado-trastuzumab Emtansine
Manufacturer : ROCHE PRODUCTS INDIA PVT LTD
Origin of Medicine : Switzerland
1 Vial(s)
PAP Information : Buy 1, get 1 Free. Contact us for latest updates.
Program Overview: ROCHE PRODUCTS INDIA PVT LTD, Patient Assistance Program (PAP) is dedicated to helping patients in need of Kadcyla 160mg injection. The program aims to provide eligible patients with access to the medication at a more affordable cost.
Program Benefits: Purchase 1 vial of Kadcyla 160mg injection, and you will receive 1 free vial. Therefore, if eligible, you will have to pay only Rs. 2,29,270 for 2 vials, which is Rs.1,14,635 per vial.
With MrMed's MRP discount of Rs.45,941 per vial and Roche’s PAP program, the overall savings is over 3 lakh rupees per purchase.
Contact us for the latest updates on this exclusive offer.
Eligibility Criteria: To qualify for the Kadcyla Patient Assistance Program (PAP), you must meet specific criteria, including having a valid prescription for ado-trastuzumab emtansine 160mg from a medical oncologist and being an Indian patient with a valid identity card. Eligibility is determined based on the diagnosed condition and program-specific requirements.
Contact Information: If you have any questions or need assistance with the application process, our dedicated patient support team is here to help. You can reach us by phone at 89391 69999 or email us at [email protected].
Please note that MrMed is not involved in the PAP program. They offer free consultations to patients to provide information about the program. Patients eligible for the PAP program by Roche can avail of it without having to purchase the medication from MrMed.
Patient Assistance Programs
Program Overview: ROCHE PRODUCTS INDIA PVT LTD, Patient Assistance Program (PAP) is dedicated to helping patients in need of Kadcyla 160mg injection. The program aims to provide eligible patients with access to the medication at a more affordable cost.
Program Benefits: Purchase 1 vial of Kadcyla 160mg injection, and you will receive 1 free vial. Therefore, if eligible, you will have to pay only Rs. 2,29,270 for 2 vials, which is Rs.1,14,635 per vial.
With MrMed's MRP discount of Rs.45,941 per vial and Roche’s PAP program, the overall savings is over 3 lakh rupees per purchase.
Contact us for the latest updates on this exclusive offer.
Eligibility Criteria: To qualify for the Kadcyla Patient Assistance Program (PAP), you must meet specific criteria, including having a valid prescription for ado-trastuzumab emtansine 160mg from a medical oncologist and being an Indian patient with a valid identity card. Eligibility is determined based on the diagnosed condition and program-specific requirements.
Contact Information: If you have any questions or need assistance with the application process, our dedicated patient support team is here to help. You can reach us by phone at 89391 69999 or email us at [email protected].
Please note that MrMed is not involved in the PAP program. They offer free consultations to patients to provide information about the program. Patients eligible for the PAP program by Roche can avail of it without having to purchase the medication from MrMed.
Introduction to Kadcyla 160mg Injection
Kadcyla 160mg Injection consists of the active ingredient Ado-Trastuzumab emtansine. It is a prescription medication used to treat HER2-positive breast cancer that has spread to other parts of the body or has not responded to other treatments. It is a combination of two drugs: trastuzumab, which is an antibody that targets HER2 receptors, and emtansine, which is a chemotherapy drug that kills cancer cells. It is indicated to treat breast cancer in the early stages as well as advanced stages, where patients develop recurrence within six months of chemotherapy treatment. This medication acts against tumours that produce more than the normal amount of a certain protein (known as HER2 protein).
Patients with residual breast cancer after chemotherapy treatment and HER2-targeted therapy have a poorer prognosis than those with no residual cancer. Report to your physician immediately if you experience side effects such as allergic reactions, unusual bleeding, etc. This medication does not show any adverse effects on the kidney. In rare cases, an infusion reaction is seen. Like all other medications, it shows mild side effects like nausea, vomiting, diarrhoea, and hair loss.
Uses of Kadcyla 160mg Injection
Kadcyla 160mg Injection is indicated for its use in the following conditions:
- Advanced and metastatic breast cancer
- Metastatic gastric cancer
Therapeutic Effects of Kadcyla 160mg Injection
Ado-Trastuzumab emtansine works by combining the targeting ability of trastuzumab, which binds to HER2-positive cancer cells, with the cell-killing effects of emtansine, a chemotherapy drug. Once this medication binds to the HER2-positive cancer cells, it releases emtansine, which then enters the cancer cells and destroys them. This process helps to slow down or stop the growth of cancer, reducing the size of tumours and potentially extending the patient's life.
Interaction of Kadcyla 160mg Injection with other drugs
Inform your healthcare provider about all the medicines you take, including prescription, over-the-counter, nutritional or vitamin supplements, and herbal products. Certain medications may interact with Kadcyla 160mg Injection and reduce effectiveness by causing undesirable side effects.
More Information about Kadcyla 160mg Injection
- Kadcyla 160mg Injection should be stored in the refrigerator at 2°C to 8°C (36°F to 46°F).
- Protected from light.
- Keep it in its original packaging until it is ready to be used.
- Keep reaching out of the reach of children and pets.
- It should be disposed of properly.
How to consume Kadcyla 160mg Injection
Kadcyla 160mg Injection is administered by a healthcare professional in a hospital or clinic setting. The dose and frequency depend on several factors, such as the individual's age, weight, overall health, and the type and stage of the cancer being treated. If a dose is missed, it should be taken as soon as possible unless it's almost time for the next scheduled dose, in which case the missed dose should be skipped, and the regular dosing schedule resumed. Do not double the dose to make up for missed doses.
Safety Advices for Kadcyla 160mg Injection
Pregnancy
Discuss with your physician before taking this Kadcyla 160mg Injection if you are pregnant or think you might be pregnant. Do not take this medicine during the pregnancy unless advised by the doctor to take as it may cause harm to the unborn baby.
Breast Feeding
Avoid breastfeeding your baby while on the treatment with Kadcyla 160mg Injection for at least seven months after the final dose.
Lungs
Kadcyla 160mg Injection safety and efficacy have not been extensively studied. So, patients with pre-existing lung conditions should consult a doctor before taking it.
Liver
Kadcyla 160mg Injection can affect liver function, and in rare cases, it can cause liver damage, including hepatotoxicity and liver failure. Therefore, it's important to inform your healthcare professional if you have any history of liver problems, such as hepatitis or cirrhosis, before starting treatment.
Alcohol
It is recommended to avoid consuming alcohol while taking Kadcyla 160mg Injection, as alcohol can increase the risk of certain side effects associated with the medication, such as stomach ulcers or gastrointestinal bleeding.
Driving
Kadcyla 160mg Injection can cause unusual tiredness and dizziness. Hence, it is advised to avoid driving or handling machinery during the treatment.
Side Effects of Kadcyla 160mg Injection
Side effects are unwanted symptoms caused by medicines. Even though all medicines cause side effects, not everyone gets them. Kadcyla 160mg Injection can cause side effects as follows:
Serious:
- Infusion reactions, including fever, chills, rash, or difficulty breathing
- Lung problems, including shortness of breath, cough, or fever
- Heart problems, including heart failure or abnormal heart rhythms
- Severe bleeding or bruising
- Nerve damage, including numbness, tingling, or weakness
- Severe allergic reactions
Common:
- Fatigue
- Nausea
- Constipation
- Muscle or joint pain
- Headache
- Fever
- Low platelet count
- High liver enzyme levels
- Low red blood cell count
- Loss of appetite
- Rash or itching
Word of Advice
If you are receiving Kadcyla 160mg Injection, it's important to be proactive in managing your treatment and monitoring your symptoms. Keep communication with your healthcare provider and report any concerns or side effects as soon as possible. Avoid getting pregnant and breastfeeding during treatment. Use effective birth control during the treatment and at least 7 weeks after the last dose. Immediately contact your healthcare provider in case of any worsening of symptoms or infusion reactions. Take steps to care for yourself physically and emotionally during treatment, and seek support from loved ones and professionals as needed. Maintain a healthy and balanced diet during treatment to support your overall health and well-being. Being informed and engaged in your treatment can help ensure the best possible outcomes and manage potential risks or complications.
FAQs
Q 1. Can Kadcyla 160mg Injection cause nerve damage?
Kadcyla 160mg Injection can cause peripheral neuropathy, a type of nerve damage that can cause tingling, numbness, or weakness in the hands and feet. If you experience these symptoms during treatment, discuss them with your healthcare provider.
Q 2. Does Kadcyla 160mg Injection cause infertility?
Kadcyla 160mg Injection can cause temporary infertility in some patients, particularly women. If fertility preservation is a concern for you, discuss this with your healthcare provider before starting treatment.
Q 3. How is Kadcyla 160mg Injection different from traditional chemotherapy?
Kadcyla 160mg Injection is a type of chemotherapy, but it is designed to target HER2-positive cancer cells specifically, which may result in fewer side effects than traditional chemotherapy. Additionally, it is given as a single medication, rather than as a combination of drugs.
Q 4. Can Kadcyla 160mg Injection be used in combination with other cancer treatments?
Kadcyla 160mg Injection may be used in combination with other cancer treatments, such as chemotherapy or targeted therapies. Your healthcare provider can help determine the best treatment plan for you based on your individual needs and medical history.
Q 5. Can I take Kadcyla 160mg Injection if I have tuberculosis?
The use of Kadcyla 160mg Injection in patients with active tuberculosis (TB) is not recommended due to the risk of worsening the TB infection. This medication can suppress the immune system, making it harder for the body to fight off infections such as TB. Before starting treatment, your healthcare provider will perform a thorough evaluation of your medical history, including screening for TB.
Q 6. Can Kadcyla 160mg Injection cause heart problems?
Kadcyla 160mg Injection can cause heart problems, particularly in patients with preexisting heart conditions or risk factors. Your healthcare provider will monitor your heart function closely during the treatment.
Fact Box of Kadcyla 160mg Injection
Molecule name: Trastuzumab
| Therapeutic class: Anti-cancer |
Pharmacological class: HER2 inhibitor | Indications: 1. Advanced and metastatic breast cancer 2. Metastatic gastric cancer |
References
- Roche Products Limited, Electronic Medicines Compendium (EMC), [Revised on Jul 2021] [Accessed on 9th April 2023], https://www.medicines.org.uk/emc/files/pil.5252.pdf
- Gunter von Minckwitz et al., Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer, N Engl J Med 2019; 380:617-628 [Accessed on 19th April 2023], https://www.nejm.org/doi/full/10.1056/NEJMoa1814017
- Barok et al., Trastuzumab emtansine: mechanisms of action and drug resistance, Breast Cancer Research 2014, 16:209, [Accessed on 19th April 2023], https://www.researchgate.net/publication/262780064_Trastuzumab_emtansine_Mechanisms_of_action_and_drug_resistance
- Genentech, Inc. U.S Food and Drug Administration (FDA) [Last Revised 3rd May 2019], [Accessed on 19 April 2023], https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125427s105lbl.pdf
Disclaimer
MrMed’s primary intention is to ensure that its consumers get information that is reviewed by experts, accurate and trustworthy. The information and contents of this website are for informational purposes only. They are not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of your doctor and discuss all your queries related to any disease or medicine. Do not disregard professional medical advice or delay in seeking it because of something you have read on MrMed. Our mission is to support, not replace, the doctor-patient relationship.
